https://www.news-medical.net/news/20220830/Research-reveals-administration-of-ineffective-COVID-19-treatments-after-FDA-deauthorization.aspx
Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use authorization for two monoclonal antibodies (bamlanivimab/etesevimab and casirivimab/imd…
Create an account or login to join the discussion